Tagrisso Osimertinib 80 mg Azd9291
Brand Name: Tagrisso
Manufactured by: AstraZeneca
Strength: 80 mg
Packing: Pack of 30 Tablets
Osimertinib mesylate (Azd9291) is a third-generation EGFR inhibitor developed for AstraZeneca. It irreversibly inhibits EGFR-T790M. It was approved by the U.S. Food and Drug Administration (FDA) on November 13, 2015 for the treatment of non-small cell lung cancer. . The chemical synthesis, preclinical pharmacology, clinical research and patent protection of osimertinib mesylate are introduced to provide reference for the development of anti-tumor drugs.
Yaodu Jingwei Information Technology (Beijing) Co., Ltd.
(Azd9291) Osimertinib mesylate (trade name Tagrisso, 1) is an epidermal growth factor receptor (EGFR) inhibitor developed by Astra Zeneca, UK, and was administered by the US Food and Drug Administration on April 16, 2014. Bureau (FDA) awarded the title of breakthrough therapy. Followed by the phase II clinical study of the tumor objective response rate and duration of response data, the FDA passed the accelerated approval process.
- Osicent launches Bangladesh Incepta Pharmaceuticals
Following the launch of AZD9291 (Oxytinib) generic drug Tagrix by Beacon Pharmaceuticals in Bangladesh, the Incepta Pharmaceutical Factory in Bangladesh launched the world's first bottled AZD9291 generic drug Osicent. We also received a sample of Osicent for the first time. Here again, we will give a brief introduction to Incepta and Osicent.
One, Osicent more convenient to use, curative effect, price close to the people
As shown in the figure above, the biggest difference between Osicent and Tagrix is the bottled form. Osicent maintains the same packaging format as the original drug. A bottle of 30 tablets is more convenient than the boxed Tagrix, and the transportation is more convenient.
From the point of view of the active ingredients of the drug, Osicent also maintains the same ingredients as the original drug, each containing 80 mg of Osimertinib. Therefore, it is comparable to the therapeutic effect of the original research drug.
From the price point of view, the original research drug Agrico Inc. Targrisso has a monthly fee of 12,750 US dollars (approximately 87,760 yuan), and Osicent affordable, China's lung cancer patients can afford treatment programs.
2. Oxitinib can effectively alleviate the disease progression after Iressa, Tarceva and Kemena resistance. The pharmacological efficacy study is clear.
In lung cancer, non-small cell lung cancer accounts for about 85% , and 50% of  Asian patients with non-small cell lung cancer have EGFR (epidermal growth factor receptor) sensitivity mutations. Therefore, many patients use Iressa, Tarceva's generic drugs or domestic Kemena, which are tyrosine kinase inhibitors (TKI), can target EGFR, and thus inhibit the growth of tumor cells. However, 60% of  patients will develop T790M mutations after long-term medications, which will invalidate Iressa, Tarceva, and Kamena and become a problem in the world.
Finally, on November 11, 2015, the US Food and Drug Administration (FDA) approved the listing of Agricola's Tagrisso (Osimertinib, AZD9291) as a weapon against T790M mutant TKI drugs. According to the results of its clinical trials, complete remission and partial remission in patients resistant to Iressa, Tarceva, and Kamena accounted for about 60% , which can save the lives of countless patients.
As shown in the figure below, the left picture shows the CT image of the lung before taking AZD9291. The right picture shows the CT image after taking AZD9291 for 8 weeks. It can be seen that the tumor cells in the lung obviously shrink and the patient's condition is greatly improved.
As shown below, pharmacically, Osicent, like Iressa, Tarceva, and Kemena, bind to key sites on the surface of EGFR (epidermal growth factor receptor) cells on the surface of tumor cells, preventing their phosphorylation leading to tumor cells. Inability to proliferate and apoptosis
Third, Incepta company is strong, strict cGMP control management, excellent product quality
The Bangladesh Incepta Pharmaceutical Factory is one of the largest pharmaceutical plants in Bangladesh. Founded in 1999, it has launched more than 600 pharmaceutical products ranging from conventional oral tablets, capsules, suspensions, eye drops, and the like to injectable biological products. All involved. As shown in the figure on the right, advanced production lines and clean GMP factories, as well as strict quality control, won the GMP of many countries including the MHRA (UK Food and Drug Administration) and the EU (EU) and many other countries' drug regulatory authorities. Certification. Its products are exported to all parts of the world, including the United Kingdom, EU member states and many developing countries.
Incepta Pharmaceuticals is well-known to Chinese patients because it produced the second-generation generic version of the drug Twinvir, and many patients with hepatitis C use Twinvir before it was launched. Good curative effect, low side-effect, stable quality, cure many Chinese hepatitis C patients, Incepta company has very good reputation among Chinese hepatitis C patients